THX Pharma Société Anonyme (EPA:ALTHX)

Market Cap	50.90M +164.3%
Revenue (ttm)	3.26M +271.6%
Net Income	-2.03M
EPS	-0.14
Shares Out	14.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,677
Open	3.400
Previous Close	3.420
Day's Range	3.360 - 3.560
52-Week Range	1.490 - 5.100
Beta	1.47
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 24, 2026

About EPA:ALTHX

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 12
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2025, EPA:ALTHX's revenue was 806,045, a decrease of -64.70% compared to the previous year's 2.28 million. Losses were -3.00 million, 70.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error